Skip to content

A randomized, multicenter study comparing the safety and efficacy of CT-ACL001, a regenerative ligament, with standard treatment in anterior cruciate ligament reconstruction

A randomized, multicenter study comparing the safety and efficacy of CT-ACL001, a regenerative ligament, with standard treatment in anterior cruciate ligament reconstruction

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2032240214
Enrollment
64
Registered
2024-07-12
Start date
2024-11-25
Completion date
Unknown
Last updated
2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with anterior cruciate ligament injury who are candidates for reconstruction surgery Anterior cruciate ligament injury, anterior cruciate ligament rupture, anterior cruciate ligament reconstruction

Interventions

Anterior cruciate ligament reconstruction using the investigational device or autologous tendon (hamstring tendon)
Anterior cruciate ligament reconstruction, CT-ACL001

Sponsors

Okazaki Ken
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Age: 18 years old or older and under 45 years old. Patients with anterior cruciate ligament injury who are candidates for reconstruction surgery.

Exclusion criteria

Exclusion criteria: Chronic anterior cruciate ligament injury (injury occurred more than 12 months ago). History of knee surgery, including anterior cruciate ligament surgery on the index side. Complication or history cruciate ligament injury on the opposite side, history of total knee arthroplasty, osteotomy around the knee, or osteosynthesis around the knee on the opposite side. Meniscus injury that requires extensive resection and is impossible to suture on the index side, collateral ligament injury or posterior cruciate ligament injury of 2 or more on the index side. Complication of osteoarthritis of the knee on the index side, KL classification 2 or higher. Complications of cartilage damage that cannot be treated by drilling or microfracture on the index side. Patients with infection in the index knee or inflammatory joint disease such as rheumatoid arthritis. Patients undergoing radiation therapy, chemotherapy, or both. Patients currently receiving treatment with systemic steroids, immunosuppressants, or both. Patients who are allergic to bovine products (e.g. meat). Patients who cannot discontinue returning to sports until 9 months after reconstruction surgery. Pregnant, breastfeeding and possibly pregnant patients. Female patients of childbearing potential and male patients who cannot agree to contraception for at least one year after reconstruction surgery. Patients who participated in other clinical trials within 4 weeks prior to reconstruction surgery.

Design outcomes

Primary

MeasureTime frame
IKDC Subjective Score

Secondary

MeasureTime frame
Anterior tibial translation. Donor site morbidity. Knee flexion strength. Tegner activity score. Incidence of additional surgery on the affected side. Graft rupture rate. Joint effusion. Adverse events/malfunction rates.

Contacts

Public ContactMitsuhide Kanemoto

CoreTissue BioEngineering Inc.

mitsuhide.kanemoto@coretissue.com+81-45-642-5455

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026